{'fraction_non_alphanumeric': 0.02844141069397042, 'fraction_numerical': 0.006825938566552901, 'mean_word_length': 5.423357664233577, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is the fourth most common cancer and the fourth leading cause of cancer-related death in China, and more than half of global ESCC cases occur in China. Camrelizumab (SHR-1210), a selective IgG4-κ monoclonal antibody against PD-1, has displayed superior efficacy to chemotherapy and a tolerable safety profile in Chinese patients with advanced or metastatic ESCC. Cutaneous immune-related adverse events (irAEs) induced by camrelizumab are always low grade and not life-threatening. Here we present the case of a Chinese patient with locally advanced ESCC who developed toxic epidermal necrolysis (TEN; also known as Lyell’s syndrome) upon treatment with camrelizumab, which was accompanied by dynamic changes in a series of auto-antibodies.